Leaders in influenza
Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of influenza globally, with extensive research and production expertise and manufacturing plants in the US, UK and Australia.
We utilise both egg and cell-based technologies for influenza vaccine production and have developed the only adjuvanted seasonal influenza vaccine for elderly populations. Our scientists continue to optimise these innovative technologies whilst working on longer-term transformational approaches to influenza protection.
As part of the CSL Group, we have been producing influenza vaccine in Melbourne, Australia since the 1940’s. Our site in Liverpool UK, is a Centre of Excellence for adjuvanted influenza vaccine manufacturing while our state-of-the-art production facility in Holly Springs US, was purpose-built to harness newer cell-based technology.
3 to 5 million
Cases of severe illness resulting from annual flu epidemics.*
potential respiratory deaths linked to seasonal flu each year.*
Annual medical care and lost labour costs in the US alone.^
Areas of expertise
We our one of the world’s largest influenza vaccine companies with a unique singular focus on influenza globally
Pandemic Response Solutions
Experts agree that there will be another influenza pandemic this century. Seqirus offers a portfolio of pandemic vaccines and services for rapid response.
Seqirus is the largest fully integrated commercialisation partner for vaccines and pharmaceuticals in Australia and New Zealand.
Antivenoms & Q fever Vaccine
Seqirus is the supplier of a unique range of antivenoms and Q fever vaccine for the Australian government.
*World Health Organisation. Influenza (seasonal) Fact Sheet, November 2018. Available online: http://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal) (Accessed March 2019)
^de Boer, P. et al, A systematic review of health economic consequences of quadrivalent influenza vaccination, Expert review of Pharmacoeconomics & Outcomes Research, Volume 17, 2017 - Issue 3. https://doi.org/10.1080/14737167.2017.1343145